Paediatric auditory brainstem implant: How we do it - Top-Institutions - MDSpire

Paediatric auditory brainstem implant: How we do it

  • By

  • Peter John Kullar

  • Simon Freeman

  • Scott Rutherford

  • Simon Lloyd

  • Martin O’Driscoll

  • Lise Henderson

  • Kerri Millward

  • Omar Pathmanaban

  • January 19, 2026

  • 0 min

Share

Top Institutions in Surgery

Brief introduction explaining scope and methodology.

  • #1

    House Ear Institute (now part of Cedars-Sinai Medical Center)
    House Ear Institute (now part of Cedars-Sinai Medical Center)

    Los Angeles, CA

    Key Differentiators

    • Otolaryngology
    • Neurotology
    • Pediatric Otology
    • Neurosurgery

  • #2

    House Ear Clinic, University of California San Francisco (UCSF)
    House Ear Clinic, University of California San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Otolaryngology
    • Neurotology
    • Pediatric Neurosurgery

  • #3

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Neurosurgery
    • Otolaryngology
    • Pediatric Surgery

  • #4

    Massachusetts Eye and Ear Infirmary, Harvard Medical School
    Massachusetts Eye and Ear Infirmary, Harvard Medical School

    Boston, MA

    Key Differentiators

    • Otolaryngology
    • Neurotology
    • Pediatric Otolaryngology

  • #5

    University of Pittsburgh Medical Center (UPMC)
    University of Pittsburgh Medical Center (UPMC)

    Pittsburgh, PA

    Key Differentiators

    • Neurosurgery
    • Otolaryngology
    • Pediatric Surgery

Original Source(s)

Paediatric auditory brainstem implant: How we do it

  • by Peter John Kullar, Simon Freeman, Scott Rutherford, Simon Lloyd, Martin O’Driscoll, Lise Henderson, Kerri Millward, Omar Pathmanaban

  • January 19, 2026

Related Content

Subcortical language localization using sign language and awake craniotomy for dominant posterior temporal glioma resection in a hearing-impaired patient

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.